hydroxychloroquine has been researched along with Carcinoma, Ductal, Pancreatic in 11 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an autophagy inhibitor." | 3.01 | SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. ( Bahary, N; Boone, BA; Fei, N; Hogg, ME; Lotze, MT; Ramanathan, R; Singhi, AD; Wen, S; Zeh, HJ; Zureikat, AH, 2021) |
| "Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome." | 1.91 | Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies. ( Abrams, SL; Cervello, M; Follo, MY; Manzoli, L; Martelli, AM; McCubrey, JA; Ratti, S, 2023) |
| " Collectively, these results indicated that the lysosome‑targeted drug combination induces multiple organelle dysfunction and exerts a marked cytotoxic effect in PDAC cells." | 1.72 | Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells. ( Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 8 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H | 1 |
| Courau, T | 1 |
| Borison, J | 1 |
| Ritchie, AJ | 1 |
| Mayer, AT | 1 |
| Krummel, MF | 1 |
| Collisson, EA | 1 |
| Stalnecker, CA | 1 |
| Grover, KR | 1 |
| Edwards, AC | 1 |
| Coleman, MF | 1 |
| Yang, R | 1 |
| DeLiberty, JM | 1 |
| Papke, B | 1 |
| Goodwin, CM | 1 |
| Pierobon, M | 1 |
| Petricoin, EF | 1 |
| Gautam, P | 1 |
| Wennerberg, K | 1 |
| Cox, AD | 1 |
| Der, CJ | 1 |
| Hursting, SD | 1 |
| Bryant, KL | 1 |
| Suzuki, S | 1 |
| Ogawa, M | 1 |
| Miyazaki, M | 1 |
| Ota, K | 1 |
| Kazama, H | 1 |
| Hirota, A | 1 |
| Takano, N | 1 |
| Hiramoto, M | 1 |
| Miyazawa, K | 1 |
| McCubrey, JA | 1 |
| Abrams, SL | 1 |
| Follo, MY | 1 |
| Manzoli, L | 1 |
| Ratti, S | 1 |
| Martelli, AM | 1 |
| Cervello, M | 1 |
| Silvis, MR | 1 |
| Silva, D | 1 |
| Rohweder, R | 1 |
| Schuman, S | 1 |
| Gudipaty, S | 1 |
| Truong, A | 1 |
| Yap, J | 1 |
| Affolter, K | 1 |
| McMahon, M | 1 |
| Kinsey, C | 1 |
| Chen, X | 1 |
| Yu, Q | 1 |
| Liu, Y | 1 |
| Sheng, Q | 1 |
| Shi, K | 1 |
| Wang, Y | 1 |
| Li, M | 1 |
| Zhang, Z | 1 |
| He, Q | 1 |
| Ji, Y | 1 |
| Liu, X | 1 |
| Li, J | 1 |
| Xie, X | 1 |
| Huang, M | 1 |
| Jiang, J | 1 |
| Liao, YP | 1 |
| Donahue, T | 1 |
| Meng, H | 1 |
| Xavier, CB | 1 |
| Marchetti, KR | 1 |
| Castria, TB | 1 |
| Jardim, DLF | 1 |
| Fernandes, GS | 1 |
| Fei, N | 1 |
| Wen, S | 1 |
| Ramanathan, R | 1 |
| Hogg, ME | 1 |
| Zureikat, AH | 1 |
| Lotze, MT | 1 |
| Bahary, N | 1 |
| Singhi, AD | 1 |
| Zeh, HJ | 1 |
| Boone, BA | 1 |
| Rosenfeldt, MT | 1 |
| O'Prey, J | 1 |
| Morton, JP | 1 |
| Nixon, C | 1 |
| MacKay, G | 1 |
| Mrowinska, A | 1 |
| Au, A | 1 |
| Rai, TS | 1 |
| Zheng, L | 1 |
| Ridgway, R | 1 |
| Adams, PD | 1 |
| Anderson, KI | 1 |
| Gottlieb, E | 1 |
| Sansom, OJ | 1 |
| Ryan, KM | 1 |
| Yang, A | 1 |
| Kimmelman, AC | 1 |
1 trial available for hydroxychloroquine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Pancreatic Ductal; Disea | 2021 |
10 other studies available for hydroxychloroquine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Topics: Animals; Autophagy; Azetidines; Carcinoma, Pancreatic Ductal; CD40 Antigens; Cell Line, Tumor; Drug | 2022 |
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Synergism; Enzym | 2022 |
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumo | 2022 |
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chloroquine; Hydroxychloroquine; Mice; Mito | 2023 |
MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Topics: Carcinoma, Pancreatic Ductal; Chloroquine; Cyclin-Dependent Kinase 4; Humans; Hydroxychloroquine; Ly | 2023 |
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Duct | 2019 |
Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cyclin-Dependent Kina | 2020 |
Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; CA-19-9 Antigen; Carci | 2021 |
p53 status determines the role of autophagy in pancreatic tumour development.
Topics: Alleles; Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Carcinoma, Pa | 2013 |
Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status.
Topics: Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Humans; | 2014 |